Literature DB >> 4823928

Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration.

A Liuzzi, P G Chiodini, L Botalla, G Cremascoli, E E Müller, F Silvestrini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4823928     DOI： 10.1210/jcem-38-5-910

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  35 in total

1.  Editorial: Bromocriptine--a changing scene.

Authors: 
Journal:  Br Med J       Date:  1975-12-20

Review 2.  Some current aspects of clinical and experimental neuroendocrinology with particular reference to growth hormone, thyrotropin and prolactin.

Authors:  M F Scanlon; M Pourmand; A M McGregor; M D Rodriguez-Arnao; K Hall; A Gomez-Pan; R Hall
Journal:  J Endocrinol Invest       Date:  1979 Jul-Sep       Impact factor: 4.256

Review 3.  Medical management of growth hormone-secreting pituitary adenomas.

Authors:  Michael S Racine; Ariel L Barkan
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

4.  Clinical and pharmacological characterization of anomalous metoclopramide-induced growth hormone secretion in insulin-dependent diabetes mellitus.

Authors:  F Caviezel; G Lepore; M L Maglio; M Croci; G Comi; L Morricone
Journal:  Acta Diabetol Lat       Date:  1989 Apr-Jun

Review 5.  Bromocriptine in the treatment of acromegaly.

Authors:  D E Bateman; W M Tunbridge
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

6.  Recent developments in the treatment of acromegaly.

Authors:  D K Lüdecke
Journal:  Neurosurg Rev       Date:  1985       Impact factor: 3.042

7.  Plasma bromocriptine levels, clinical and growth hormone responses in Parkinsonism.

Authors:  P Price; A Debono; J D Parkes; C D Marsden; J Rosenthaler
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

Review 8.  Somatostatin analogs in medical treatment of acromegaly.

Authors:  Michael S Racine; Ariel L Barkan
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

9.  Variation of blood glucose and serum growth hormone, prolactin and insulin in subjects with insulin-dependent diabetes, after OGTT and pretreatment with 2-Br-alpha-ergocryptine.

Authors:  A Gnudi; R Lugari; M G Cavazzini
Journal:  Acta Diabetol Lat       Date:  1977 May-Aug

10.  Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.

Authors:  M Ishibashi; T Yamaji
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.